Danicopan add-on therapy for extravascular hemolysis in a patient with paroxysmal nocturnal hemoglobinuria receiving ravulizumab
Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by complement-mediated hemolysis. Although C5 inhibitors effectively control intravascular hemolysis, some patients develop clinically significant extravascular hemolysis (EVH) because of upstream C3 deposition. A 56-year-old woman was diagnosed with PNH in 201...